Products
Suppliers
Sourcing Requests

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

亚洲欧美不卡高清在线观看,伊人久久大香线蕉午夜av,亚洲综合色区在线观看,中文在线中文a,真正免费的毛片

<cite id="tyhsy"></cite>

<sub id="tyhsy"><p id="tyhsy"></p></sub>

<sup id="tyhsy"></sup>

You are here: Industry Insights > Orelabrutinib: A Novel BTK inhibitor

News List

Orelabrutinib: A Novel BTK inhibitor David Orchard-Webb
March 01, 2024
Orelabrutinib, developed by InnoCare Pharma, is an orally bioavailable, second-generation Bruton's tyrosine kinase (BTK) inhibitor.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

About Us: About PharmaSources; Terms of Service; Privacy Policy; Event Data Sharing Notice; Intellectual Property; Media Partners

Buy: Search Products; Post Sourcing Requests; Search Suppliers; CAS Search

Sell: Member Application; Advertising; Post Products; EZSourcing

Events: CPHI China; PMEC China; Conferences; Search Events

Help: FAQ; Contact Us; Feedback

Copyright 2006-2025 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved) 滬ICP備05034851號(hào)-182 滬公網(wǎng)安備31010402010101號(hào)
Links：
CCCMHPIE SJGLE.com JJGLE.COM JDGLE.COM XIUGLE.COM DENGGLE.COM HPGLE.COM
Follow Us：
Pharma Sources Insight January 2025

PharmaSources Customer Service

<legend id="hpdyu"><abbr id="hpdyu"></abbr></legend>

<cite id="hpdyu"><track id="hpdyu"></track></cite>

<sub id="hpdyu"></sub>